ArticleScience progress
First-trimester β-hCG, PAPP-A, and NLR in relation to preeclampsia and perinatal outcomes: A case-control study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo examine whether first-trimester PAPP-A, free β-hCG, NLR, and PLR are associated with subsequent development of PE, and among women with PE, whether these biomarkers are associated with adverse perinatal outcomes.MethodsIn this retrospective case-control study, we analyzed 350 primigravid women, including 175 with PE (cases) and 175 with uncomplicated pregnancies (controls). All participants had singleton gestations and available first-trimester (11 + 0 to 13 + 6 weeks) serum measurements of PAPP-A, free β-hCG, and complete blood count. Univariable and multivariable logistic regression models assessed associations of biomarkers with PE and, separately among PE cases, with the composite adverse perinatal outcome. Receiver operating characteristic (ROC) curve analysis quantified discriminative performance.ResultsIn multivariable analysis, first-trimester free β-hCG (OR = 1.358, 95% CI 1.206-1.530), PAPP-A (OR = 0.756, 95% CI 0.691-0.828), and NLR (OR = 1.655, 95% CI 1.214-2.256) were associated with PE. The combined model including these three markers showed improved discrimination for PE (AUC=0.793) compared with any marker alone. Among women with PE, higher β-hCG (OR = 1.489, 95% CI 1.242-1.784), elevated NLR (OR = 1.562, 95% CI 1.075-2.268), and lower PAPP-A (OR = 0.794, 95% CI 0.696-0.906) were associated with the adverse composite outcome in multivariable analysis. The multivariable model including these markers demonstrated an AUC of 0.804 for discrimination of the adverse composite outcome.ConclusionsFirst-trimester levels of PAPP-A, free β-hCG, and NLR may be associated with the subsequent development of PE and with adverse perinatal outcomes among affected women. These findings suggest potential biological relevance but do not establish clinical utility and should be interpreted with caution given the observational study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.